Evidence map›Paper›PMID 33671106›Full record

ArticleInternational journal of molecular sciences2021

Synthesis and Anticancer Activity of Mitotic-Specific 3,4-Dihydropyridine-2(1

Magdalena Perużyńska, Aleksandra Borzyszkowska-Ledwig, Jacek G Sośnicki, Łukasz Struk, Tomasz J Idzik, Gabriela Maciejewska, Łukasz Skalski, Katarzyna Piotrowska, Paweł Łukasik, Marek Droździk and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Magdalena PerużyńskaDepartment of Experimental and Clinical Pharmacology, Pomeranian Medical University in Szczecin, Powstanców Wielkopolskich 72, 70-111 Szczecin, Poland.
Aleksandra Borzyszkowska-LedwigDepartment of Organic and Physical Chemistry, Faculty of Chemical Technology and Engineering, West Pomeranian University of Technology, Szczecin, Al. Piastów 42, 71-065 Szczecin, Poland.
Jacek G SośnickiDepartment of Organic and Physical Chemistry, Faculty of Chemical Technology and Engineering, West Pomeranian University of Technology, Szczecin, Al. Piastów 42, 71-065 Szczecin, Poland.
Łukasz StrukDepartment of Organic and Physical Chemistry, Faculty of Chemical Technology and Engineering, West Pomeranian University of Technology, Szczecin, Al. Piastów 42, 71-065 Szczecin, Poland.ORCID 0000-0003-1474-5524
Tomasz J IdzikDepartment of Organic and Physical Chemistry, Faculty of Chemical Technology and Engineering, West Pomeranian University of Technology, Szczecin, Al. Piastów 42, 71-065 Szczecin, Poland.
Gabriela MaciejewskaFaculty of Chemistry, Wrocław University of Technology, Wybrzeże Wyspiańskiego 27, 50-370 Wrocław, Poland.
Łukasz SkalskiDepartment of Experimental and Clinical Pharmacology, Pomeranian Medical University in Szczecin, Powstanców Wielkopolskich 72, 70-111 Szczecin, Poland.
Katarzyna PiotrowskaDepartment of Physiology, Pomeranian Medical University in Szczecin, Powstanców Wielkopolskich 72, 70-111 Szczecin, Poland.
Paweł ŁukasikDepartment of Medical Chemistry, Pomeranian Medical University in Szczecin, Powstanców Wielkopolskich 72, 70-111 Szczecin, Poland.
Marek DroździkDepartment of Experimental and Clinical Pharmacology, Pomeranian Medical University in Szczecin, Powstanców Wielkopolskich 72, 70-111 Szczecin, Poland.
Mateusz KurzawskiDepartment of Experimental and Clinical Pharmacology, Pomeranian Medical University in Szczecin, Powstanców Wielkopolskich 72, 70-111 Szczecin, Poland.
Pomeranian Medical University · PLWest Pomeranian University of Technology in Szczecin · PLWrocław University of Science and Technology · PL

Funding

Narodowe Centrum Nauki 2016/23/N/NZ7/02599
6 · The paper itself

Abstract

Most anticancer drugs target mitosis as the most crucial and fragile period of rapidly dividing cancer cells. However the limitations of classical chemotherapeutics drive the search for new more effective and selective compounds. For this purpose structural modifications of the previously characterized pyridine aalog (

Indexed as

Cell Cycle CheckpointsCell ProliferationAntineoplastic AgentsApoptosisDihydropyridinesDrug DesignHumansMelanomaMitosisMolecular StructureStructure-Activity RelationshipThionesTubulin ModulatorsTumor Cells, CulturedAntineoplastic AgentsDihydropyridinesThionesTubulin Modulatorsanticancer agentscolchicine-binding sitedihydropyridinemitotic spindletubulin inhibitors

Identifiers

PMID33671106
PMCPMC7957618
OpenAlexW3135017152

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.